Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas.
The patho-physiological role of somatostatin receptor subtypes (sst) in neuro endocrine diseases has gained enhanced scientific interest in the past few years. The development of novel somatotropin-release inhibiting factor analogs, both sst-specific and universal ligands, seem promising as a tool to further increase fundamental insights in sst function. Eventually, this research should result in novel medical therapeutic opportunities in patients suffering from neuro-endocrine diseases. In the present review, the functional role of sst in all types of pituitary adenomas, based on recent preclinical and clinical studies, is being discussed.
van der Hoek
Joost
J
Lamberts
Steven W J
SWJ
Hofland
Leo J
LJ
D000236:Adenoma / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled / Q000187:drug effects / Q000502:physiology; D017481:Receptors, Somatostatin / Q000187:drug effects* / Q000502:physiology; D013004:Somatostatin / Q000031:analogs & derivatives*
D043562:Receptors, G-Protein-Coupled; D017481:Receptors, Somatostatin; D013004:Somatostatin